FDA Oxycontin & Oxycodone Expert
What is an Expert on Oxycontin and Oxycodone?
Oxycodone and Oxycontine is a newer opiate which, like all opiates, is prone to abuse. Oxycodone is different from other opiates in that it usually does not cause sedation, and may even cause centralized stimulation, as compared to other opiates. Oxycodone can be a very dangerous drug if used inappropriately. Oxycodone is indicated for long-term pain control and is difficult to find generically in pharmacies. There are many active litigation cases on oxycontin.
An expert on Oxycontin and Oxycodone is someone who understands all aspects of these drugs, from the clinical trial phase, to the actual drug labeling on these that lists the potential hazards. Having an expert that’s worked with the FDA is beneficial for litigations and lawsuits as they will know all the myriad and complicated regulations regarding these drugs.
What is are opiates?
Opiate drugs are a class of drugs used to treat pain and can become addictive if prescribed incorrectly. Opiate drugs include morphine, codeine, codeine, hydrocodone, opium, cocaine, amobarbital, glutethimide, pentobarbital, and secobarbital, hydromorphone, oxycontin, nucynta, hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (Percodan®), fentanyl (Duragesic®), amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), methylphenidate (Ritalin®)
Purdue Pharma L.P. is the maker of the slow-release version of oxycodone known as OxyContin.
Purdue Pharmaceuticals has been found to mislead physicians, pharmacists and patients over a period of five years by claiming that OxyContin formulation of the narcotic oxycodone is less addictive than other narcotic painkillers because it has a long-acting time-released formula.
OxyContin was and is a highly abusable, highly addictive, and potentially dangerous narcotic drug.
Even though the company was warned by health professionals, the media and members of its sales force, Perdue enacted a fraudulent marketing campaign that promoted OxyContin pharmacology as less addictive, less subject to abuse and less likely to cause withdrawal when they knew in fact that that was not true.
Purdue Pharma is a privately-owned company, and its only prescription drug is the slow-release pharmacology form of oxycodone marketed under the trade name OxyContin.
Executives at Purdue say they were unaware that company sales representatives were making such a claim about the drug. As it turned out, OxyContin was no less addictive than oxycodone or other narcotic painkillers.
OxyContin pharmacology was prone to abuse when the time-released mechanism was negated by crushing the tablet, or otherwise removing the outer coating.
Thousands of people have become addicted to OxyContin and died from overdoses since the drug’s release. Also, the over-promoting of OxyContin begun America’s epidemic of oxycodone-related drug death.
In addition to over-prescribing, criminal activity were fueled largely by pharmacy robberies, doctor-shopping patients and youths raiding medicine cabinets
OxyContin and other prescription painkillers have fueled a surge in drug overdoses, which in 2009 claimed 39,147 lives, surpassing traffic accidents as a leading cause of preventable deaths.
OxyContin/oxycodone pharmacology was the most cited drug as the cause of prescription drug overdose.
Despite its suspicions, Purdue Pharma continued to profit from prescriptions written by these physicians, many of whom were prolific prescribers of OxyContin.
The database as been compiled since 2002 and contains the names of approximately 2,000 physicians, which suggests that Purdue has long known that physicians also play a significant role in the crisis.
These 2,000 prescribers could be responsible for a large portion of the nation’s black market for OxyContin and oxycodone.
Purdue Pharmaceuticals agreed to pay $19.5 million to 26 states and the District of Columbia to settle complaints that it falsely marketed and encouraged physicians to overprescribe OxyContin for generalized pain conditions that did not require the use of narcotic analgesics.
Also, Purdue Pharma L.P., its president, top lawyer and a former chief medical officer will pay $634.5 million in fines for claiming the drug was less addictive and less subject to abuse than other pain medications.
This is a fine minimal considering that Purdue Pharma is not publically traded, and has made more than $27 billion from its marketing of its OxyContin version of oxycodone.
Contact an experienced oxycontin expert and FDA expert here.